Medical Condition News

RSS

Much remains to be done for autism spectrum disorders, say experts

Scientific understanding and medical treatments for autism spectrum disorders (ASDs) have advanced significantly over the past several years, but much remains to be done, say experts from the Center for Autism Research at The Children's Hospital of Philadelphia who published a scientific review of the field today.

15 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has enrolled the first patients in Phase III clinical trials for its autism treatment, CM-AT. The first clinical trial patients have been enrolled at Lake Mary Pediatrics in Orange City, Florida, one of 12 clinical trial sites with a total 170 children across the country.

15 Oct 2009

Control and coordination may aid multiple sclerosis patients perform daily activities independently

While gripping, lifting or manipulating an object such as drinking from a cup or placing a book on a shelf is usually easy for most, it can be challenging for those with neurological diseases such as multiple sclerosis or Parkinson's, or for people who had a stroke.

15 Oct 2009

More than half RCTs do not report vital information about study populations race, says study

A new study recently published online by the American Heart Journal shows that more than half of all randomized clinical trials, or RCTs, for cardiovascular disease are not reporting vital information about the study populations race or ethnicity. NYU School of Medicine researchers found that out of the 156 cardiovascular disease RCTs analyzed, only 35% of trials reported any information on race or ethnicity between 1970 and 2006. From 2000 to 2006, 46% of trials included that information.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

Cardium Therapeutics today reported positive data from its Matrix Phase 2b clinical trial of Excellarate(TM) for the potential treatment of patients with chronic non-healing diabetic foot ulcers based on the Company's Gene Activated Matrix (GAM) technology platform.

15 Oct 2009

ValenTx to present its first clinical study for the treatment of morbid obesity

ValenTx, Inc. announces the presentation of the first clinical study of their endoluminal approach for the treatment of morbid obesity at the 2009 American College of Surgeons Clinical Congress.

15 Oct 2009

NIH awards grant to conduct genetic drug research on cancer and heart disease

A Virginia Tech chemist has been awarded a $2.3 million grant from the National Institutes of Health (NIH) to conduct research that will aid in the development of new heart disease and cancer medicines that have fewer side effects.

15 Oct 2009

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

ZyStor Therapeutics, Inc., a biotechnology company developing a new class of targeted protein therapeutics for the treatment of Lysosomal Storage Diseases using the Company's proprietary Glycosylation Independent Lysosomal Targeting technology, today announced that it has received clearance from the U. S. Food and Drug Administration to proceed into a clinical trial for its first drug candidate, ZC-701, an enzyme replacement therapy for the treatment of Pompe disease.

14 Oct 2009

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

Ever wonder how your eyes adjust during a blackout? When we go from light to near total darkness, cells in the retina must quickly adjust. Vision scientists at Washington University School of Medicine in St. Louis have identified an intricate process that allows the human eye to adapt to darkness very quickly. The same process also allows the eye to function in bright light.

14 Oct 2009

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Doctors in Latvia have begun treatments using the region's first Novalis Tx(TM) radiosurgery platform from Varian Medical Systems and BrainLAB. Two prostate cancer patients have been treated using Varian's RapidArc® radiotherapy technology at the Riga Eastern Clinical University Hospital.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Children with low birth weight are at a higher risk of developing asthma later in life, says study

A new study from the medical university Karolinska Institutet in Stockholm shows that children born with low birth weight are at a higher risk of developing asthma later in life. The study, which is published in the journal Pediatrics, is based on data on the incidence of asthma in 10,918 twins from the Swedish Twin Registry.

14 Oct 2009

HERO House granted 501 (c) (3) status by the Federal Government

HERO House, a consumer-driven advocacy and vocational center for persons suffering from severe mental illness, announced today, that it has become a free-standing not-for-profit agency and has been granted 501 (c) (3) status by the Federal Government designated as a public charity eligible to receive tax-deductible gifts and donations.

14 Oct 2009

MUC1 protein defends against the stomach ulcer bacterium, according to study

A special protein in the lining of the stomach has been shown to be an important part of the body's defense against the stomach ulcer bacterium Helicobacter pylori in a new study from the Sahlgrenska Academy at the University of Gothenburg. The discovery may explain why the bacterium makes some people more ill than others.

14 Oct 2009

Medical Condition News

Much remains to be done for autism spectrum disorders, say experts

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

Curemark commences enrollment in Phase III CM-AT clinical trials for autism treatment

Control and coordination may aid multiple sclerosis patients perform daily activities independently

More than half RCTs do not report vital information about study populations race, says study

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Positive data from Cardium Therapeutics' Matrix Phase 2b Excellarate trial

ValenTx to present its first clinical study for the treatment of morbid obesity

NIH awards grant to conduct genetic drug research on cancer and heart disease

FDA approves ZyStor Therapeutics' ZC-701 for Phase I human safety trial

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

EMEA grants ArQule's ARQ 197 orphan drug designation

Vision scientists identify an intricate process that allows the human eye to adapt quickly to darkness

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Breakthrough in pancreatic cancer treatment

Children with low birth weight are at a higher risk of developing asthma later in life, says study

HERO House granted 501 (c) (3) status by the Federal Government

MUC1 protein defends against the stomach ulcer bacterium, according to study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News